News

US FDA extends review of GSK's blood cancer drug
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.
Fierce Pharma1h
FDA delays Blenrep decision, putting GSK's multiple myeloma comeback dreams on ice
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
GSK says US FDA extends review period for Blenrep BLA until October
(Alliance News) - GSK PLC on Wednesday said the US Food & Drug Administration has extended the review period for Blenrep combinations in relapsed/refractory multiple myeloma after an advisory ...
Acadia Healthcare, Henry Schein, The Pennant Group, Ziff Davis, and Atlassian Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a ...
StockStory.org on MSN2h
Thermo Fisher (TMO) Shares Skyrocket, What You Need To Know
Shares of life sciences company Thermo Fisher (NYSE:TMO) jumped 12.3% in the afternoon session after the company reported ...
RFK Jr. formally orders removal of thimerosal from all flu vaccines
Following a recommendation from a panel of CDC advisors, HHS Secretary Robert F. Kennedy Jr. on Wednesday ordered that the ...